Recent News
Read ArticleDr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.
Knee pain: JAMA review
- 5% PCP visits knee pain
- Knee OA ~654 million worldwide
- Patellofemoral pain: <40 yrs & physically active; pain on squat
- Meniscal tears in 12% adults (McMurray 61% sensitive; 84% specific; Joint line tender 83% sensitive; 83% specific) https://t.co/2fdpl464mb
Dr. John Cush @RheumNow ( View Tweet)
Prospective study of 305 Consecutive newly diagnosed axSpA pts (55% male; Dx delay 6 yrs; 75% B27+). 56% w/ r-axSpA more male w/ hi CRP. nr-axSpA had more inflam LBP, +FHx SpA. SpA Dx made without sacroiliitis in 12%; only 2/38 later developed sacroiliitis https://t.co/xPlGwZ7Kjk https://t.co/2TBQALvxsG
Dr. John Cush @RheumNow ( View Tweet)
Anifrolumab (Saphnelo) approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus based on SC-TULIP study. Presumeably, all prior CRL issues resolved to FDA satisfaction... https://t.co/ZtZmJLcGYa https://t.co/4B2YDpFaep
Dr. John Cush @RheumNow ( View Tweet)
Which autoimmune condition carries the highest relative risk for lymphoma? Test your knowledge in the latest RheumIQ quiz at https://t.co/TBlB4pmnKa https://t.co/sx8fpdHgHN
Dr. John Cush @RheumNow ( View Tweet)
Review of GLP-1 Receptor Agonists in Psoriasis
Psoriasis is a chronic immune-mediated inflammatory disease plaqued by systemic comorbidities that increase morbidity, mortality, and treatment complexity. Obesity is a significant contributor to psoriatic disease. https://t.co/R1Uutdjcvz
Dr. John Cush @RheumNow ( View Tweet)
FDA Targeting the Safety of Avacopan
The future of avacopan is up in the air. In April, the FDA issued a drug safety warning, previously requesting that Amgen to pull its rare disease drug Tavneos from the market. Now, there appears more pressure to remove it from the market. https://t.co/4PyIoqwNIL
Dr. John Cush @RheumNow ( View Tweet)
APR: Steroids
https://t.co/FxqGaijo6w https://t.co/OrybGNXsdf
Links:
Dr. John Cush @RheumNow ( View Tweet)
EULAR Recommendations for Physical Activity in Arthritis
EULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA).
https://t.co/RFECflCUgf https://t.co/Da7D6KpN6q
Dr. John Cush @RheumNow ( View Tweet)
Among 1074 #PsA tested annually, RF positivity was found in 16.1% overall (5.1% RF+ at baseline). RF+ rediced odds of MDA (OR 0.53) w/ incr risk of bDMARD discontinuation (OR 2.65) https://t.co/RS3BvufE7F https://t.co/cxKk2xZmoS
Dr. John Cush @RheumNow ( View Tweet)
COVID Virus Persistence with DMARD Use
MedPage Today
Drugs commonly used to treat systemic autoimmune rheumatic diseases (SARDs) may keep the SARS-CoV-2 circulating after COVID-19 infection in patients with these conditions, with researchers documenting substantially increased viral antigen persistence compared with other post-COVID patients.
Read Article
Synovial tissue study from 244 #OA pts undergoing surgery, finds variable synovial pathotypes - High-grade synovitis in 64% (55% lympho-myeloid, 12% diffuse-myeloid, 33% pauci-immune). Lympho-myeloid had highest inflammation, incr by high BMI. https://t.co/cc0Z3KWtY0 https://t.co/zf7r23KGCy
Dr. John Cush @RheumNow ( View Tweet)
RA is significantly associated with an increased risk of osteoporotic fractures (OPF) -RR 1.47 (1.32–1.64), for both female (1.39) & male(1.69) pts. Metanalysis of OPF in RA (7 cohort studies, 12,408pts). https://t.co/XP719A3ZM6 https://t.co/40phL7K9EB
Dr. John Cush @RheumNow ( View Tweet)
Neoplasia and Autoimmune Disease
Malignancy rivals cardiovascular disease as a leading cause of death in patients with systemic autoimmune diseases. Chronic inflammation and immune dysregulation can drive oncogenesis, while antitumor immune responses can trigger autoimmune https://t.co/uIsVl1N1hH
Dr. John Cush @RheumNow ( View Tweet)
Switch or Cycle - Upadacitinib vs Adalimumab in Refractory RA
After the first tumor necrosis factor inhibitor (TNFi) failure, patients with active rheumatoid arthritis (RA) responded by switching to upadacitinib, compared to cycling to a second TNFi, adalimumab. https://t.co/mEaUcBD2ZK
Dr. John Cush @RheumNow ( View Tweet)
Mexico study of SLE mortality in kids. Betw 2000-23, SLE accounted for 637/280,334 child deaths. Females (80%) had 4X higher deaths than males (ASMR 0.13 vs 0.03). No consistent trend in time for mortality. https://t.co/gkoXG90nLx https://t.co/BB0JhTHFKf
Dr. John Cush @RheumNow ( View Tweet)
Review of GLP-1 Receptor Agonists in Psoriasis
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed cardiometabolic medicine and are now attracting intense interest in inflammatory disorders.
Read Article
A man spends 50 years teaching at MIT.
He knows his time is running out.
So he records one last lecture — everything he knows, distilled into a single hour.
He died 5 months later.
This is that lecture.
The most important hour you'll watch this week. 👇
Bookmark it for later https://t.co/tRUH05ysSt
Suryansh Tiwari @Suryanshti777 ( View Tweet)
APR: Methotrexate
Companion slide deck for the Advanced Practice Rheum: Methotrexate video, featuring Dr. Jack Cush.
https://t.co/8422FKN4dq https://t.co/6gVS7dA8Gi
Links:
Dr. John Cush @RheumNow ( View Tweet)
True or False: Low-dose aspirin given at giant cell arteritis diagnosis is associated with a lower risk of major adverse cardiovascular events. Put your answer to the test in the latest RheumIQ quiz at https://t.co/XLPVoyCbLB. https://t.co/C5CSwuv5mF
Dr. John Cush @RheumNow ( View Tweet)
From the Blog
Podcasts
Great Lectures; Great Presentations
DERM on RheumNow (April 2026)-
Follow the Money (4.23.2026)
-
Prescribing Lessons (4.17.2026)
Therapeutic Updates
Expert insights on the 2024 ACR Guideline recommendations for lupus nephritis
Sponsored by Aurinia
Two experts in lupus care offer a balanced perspective on applying the updated ACR Guideline recommendations and the clinical nuances of managing lupus nephritis.
Read Post
Poster Hall
